Pancreatic Cancer Research

ResearcherUniversity of OttawaActive in the last 2 years

Rachel Anne Goodwin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0250-8479; OpenAlex author ID A5014239053. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 3 papers

Papers 9

  1. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113176↗
  2. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  3. Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use. Last author DOI 10.3390/curroncol32030128↗
  4. Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline. Co-author DOI 10.3390/curroncol30070482↗
  5. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Co-author DOI 10.1038/s41467-022-33718-7↗
  6. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo-22-86↗
  7. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? Co-author DOI 10.1158/1078-0432.ccr-20-1042↗
  8. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Co-author DOI 10.1158/1078-0432.ccr-20-2831↗
  9. BRCA mutated pancreatic cancer: A change is coming. First author DOI 10.3748/wjg.v27.i17.1943↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer Jane Knox · 6 shared papers, 2021–2025 · strength 0.76
  2. Steve Gallinger · 6 shared papers, 2021–2025 · strength 0.76
  3. Joanna M. Karasinska · 5 shared papers, 2021–2025 · strength 0.64
  4. Janessa J. Laskin · 5 shared papers, 2021–2025 · strength 0.64
  5. Oliver F. Bathe · 5 shared papers, 2021–2025 · strength 0.64
  6. James Thomas Topham · 5 shared papers, 2021–2025 · strength 0.64
  7. Grainne Mary O'Kane · 5 shared papers, 2021–2025 · strength 0.64
  8. David F. Schaeffer · 5 shared papers, 2021–2025 · strength 0.64
  9. Daniel John Renouf · 5 shared papers, 2021–2025 · strength 0.64
  10. Faiyaz Notta · 5 shared papers, 2021–2025 · strength 0.64
  11. Steve E. Kalloger · 4 shared papers, 2021–2025 · strength 0.47
  12. Erica S. Tsang · 4 shared papers, 2021–2025 · strength 0.46
  13. Sandra Elisabeth Fischer · 2 shared papers, 2022–2025 · strength 0.29
  14. Kyaw Lwin Aung · 2 shared papers, 2022–2025 · strength 0.29
  15. Hassan A. Ali · 2 shared papers, 2022–2025 · strength 0.28
  16. Akmal Ghafoor · 1 shared paper, 2025 · strength 0.25
  17. Karen E. Mulder · 1 shared paper, 2025 · strength 0.25
  18. Petr Kavan · 1 shared paper, 2025 · strength 0.25
  19. Joanna Gotfrit · 1 shared paper, 2025 · strength 0.25
  20. Shahid Ahmed · 1 shared paper, 2025 · strength 0.25
  21. Michael N. Rosen · 1 shared paper, 2021 · strength 0.22
  22. Michael M. Vickers · 1 shared paper, 2021 · strength 0.22
  23. Hui‐Li Wong · 2 shared papers, 2021–2022 · strength 0.20
  24. Khalid Hirmiz · 1 shared paper, 2023 · strength 0.19
  25. Aamer Mahmud · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.